Support NET Research
The Neuroendocrine Tumor Research Foundation (NETRF) is the leading funder of neuroendocrine tumor (NET) research, having funded more than $34 million in research projects aimed at advancing improved treatments for neuroendocrine tumors. NETRF funds are solely provided by private donations from around the globe. There are many ways to support neuroendocrine tumor (NET) research, such a making a gift, volunteering, or hosting a fundraising event. We hope that the information you find on this page is helpful and will entice you to take the next step in getting involved with NETRF.
Your gift will fund world-class research, empower and educate NET survivors and families and bolster the field of NET research. Learn more about the impact of your gift .
COVID-19 — We Need Your Help
With COVID-19 affecting families around the globe, NETRF needs your support now more than ever. While we all adjust to different routines of school closings, working from home, and cancellation of activities, NET research must continue and not slow down. Giving online is a simple and safe way to make your donation today. Please visit our Give Now page to support NET research. Thank you!
For questions about making your gift, please contact our team at firstname.lastname@example.org
The latest in NET News
From Education to Experience: How one family’s NET experience led to better educational resources for NET patients and families.
“In 2012, my husband was diagnosed with a neuroendocrine tumor (NET) cancer. At that time, there was little information and few treatment options,” said Suzanne Ludlow, NETRF Board Member and generous benefactor of NETRF’s second edition of “Neuroendocrine Cancer: A Guide for Patients and Families.” Suzanne lost her beloved husband Vincent in 2017, but she’s honoring his life while supporting other patients and families navigating NETs as a new member of the NETRF Board of Trustees. Read more about Suzanne and Vincent’s story here.
A new clinical trial being conducted at a single center in Switzerland aims to explore a therapy using a novel somatostatin receptor subtype 2 antagonist labelled with Terbium-161 (161Tb-DOTA-LM3). The study is sponsored by University Hospital, Basel, in collaboration with the Swiss National Science Foundation and the Paul Sherrer Institute and builds upon research funded by NETRF.
Study Focuses on Matching Patients with Rare Cancers and Cancer of Unknown Primary to Targeted Treatments
A patient advocacy-led clinical research study aims to determine if patients who have rare tumors can benefit from matched molecular therapy based on the results of their genomic profiling. Patients with neuroendocrine tumors and unknown primaries may be eligible for this study. Sponsored by the TargetCancer Foundation, in collaboration with Foundation Medicine Inc., the TCF-001 TRACK (Target Rare Cancer Knowledge) Study uses next-generation sequencing to develop a comprehensive genomic profile of each participant’s tumor as well as their plasma circulating cell-free DNA (blood).